The opening meeting of a US Food and Drug Administration (FDA) inspection lasts only a matter of minutes, but two QualityHub experts say it does more to set the tone of an inspection than almost anything that follows.
QHub Principal Consultant Dan McMinn says most of what makes an opening meeting effective isn’t complicated. It’s basic preparation, done consistently, well before an investigator ever arrives.
“Having a well-defined inspection procedure makes all the difference – one that spells out your notifications, what happens the moment an investigator shows up at the front door, and that front-line staff know to escort them straight to the inspection ‘front room,’” McMinn said. “All of those things make a good first impression.”
The front room is a designated area in a company’s facility where investigators carry out the majority of their work while on site. It’s also where the firm’s representatives respond to the FDA’s questions and provide requested information, among other tasks. (Related Story: “Choosing the Right ‘Front Room’ Host for an FDA Inspection,” QualityHub, Aug. 25, 2026.)
Have a Plan Before FDA Knocks on the Door
McMinn said companies should have a standing plan for how they’ll organize once an investigator arrives, including who’ll be in the front room, who’ll speak to which parts of the quality system, and how quickly the company can mobilize.
“It’s critical to have a constantly maintained list of your Subject Matter Experts [SMEs] and who speaks to which part of the QMS [Quality Management System], ready in advance,” he said. “You need to know who you’re bringing in front of an investigator before it happens.”
That preparation extends to logistics that are easy to overlook. McMinn recommends having standard records, the quality manual, and a current corrective and preventive action (CAPA) list among them, staged and ready to hand over quickly, because investigators often start there. He said companies are generally expected to have the inspection underway within about 20 minutes of an investigator’s arrival, which isn’t realistic without that groundwork already in place.
“You want to be timely in meeting with the investigator, bring in the right people to set up your opening meeting, and have a good, well-thought-out opening presentation.” – Dan McMinn
“Having a lot of that information pre-staged is good,” McMinn said. He added that under the FDA’s Quality Management System Regulation (QMSR), companies should also have a documented plan showing how the site manages quality, including quality culture, quality procedures, and other quality activities.
That planning should also address a few practical details worth preparing for in advance. In some cases, it may be appropriate to have product samples on hand for discussion during the opening meeting. When that’s the case, samples should be clearly labeled “Demo Only – Not for Resale” or with other applicable labeling, and the company’s inspection procedure should spell out how to document if FDA asks to take a product sample.
That procedure should also cover how the company will review the FDA Form 482 “Notice of Inspection” when it’s presented, and who’s authorized to sign any documents the investigator requests during the visit – topics that apply just as much to the closing meeting as they do to the opening one. (Related Story: “The Most Dangerous Part of an FDA Inspection? The Closeout Meeting,” QualityHub, Sept. 14, 2026.)
Setting the Room and the Tone
Once the investigator arrives, McMinn said the details of the front room matter more than companies sometimes realize.
“You want to have a professional conference room set up. You don’t want things written on the whiteboards,” he said. “You want to be timely in meeting with the investigator, bring in the right people to set up your opening meeting, and have a good, well-thought-out opening presentation.” (Related Story: “Before FDA Arrives, Get Your Response Team Right, Part 1: The Host, the Rules, the Request Manager,” QualityHub, Sept. 2, 2026.)
McMinn said the goal of that presentation is to orient the investigator, not to get into specifics or areas of potential concern.
“‘Here’s the site, here’s how big it is, here’s the number of employees, here’s the products we manufacture’ – that level of detail, along with the company’s expectations around safety, is what belongs in an opening meeting presentation,” he said.
Being prepared for that first exchange sends an unmistakable signal, McMinn said. “If you’re prepared for that and you have everything ready to go, it sends the message that you’re a professional. You know what to do, and you’re ready for the inspection.”
What to Include in the Presentation, and What to Leave Out
McMinn described a fairly consistent list of what belongs in an opening presentation. It should include the facility address, FDA registration number, applicable certifications from ISO (the International Organization for Standardization), approximate employee count, and a high-level look at how the site is organized, including key roles.
Scope is also worth addressing directly, he said. A site that doesn’t perform design and development, for example, should say so upfront, along with any other activities, such as installation and servicing, that fall outside its scope. From there, McMinn said, a brief overview of the products manufactured and shift structure rounds out what a company needs to share.
“Just include the basics,” he advised.
QualityHub Principal Consultant Anne Albertz, who corroborates much of McMinn’s approach from her own experience hosting and being part of FDA inspections, said the opening presentation is also the right place to set expectations around how the company will manage the investigator’s time on site.
That includes informing investigators that they’ll be escorted through the facility for the duration of their visit. (Related Story: “Before FDA Arrives, Get Your Response Team Right, Part 2: Scribes, Escorts, and SMEs Round Out the Team,” QualityHub, Sept. 2, 2026.)
“All of that should be in your opening presentation so the investigator won’t be surprised,” Albertz said. “Telling investigators these types of things upfront rather than explaining them in the moment is what keeps a standard practice from feeling like an ambush later on.”
The Opening Meeting is a Two-Way Conversation
The opening meeting isn’t only a chance to present – it’s also an opportunity to ask the investigator questions that can help a company understand the scope and direction of the inspection ahead.
Confirming the purpose of the inspection, for example, whether it’s routine, for-cause, or tied to a specific complaint, can help a company gauge whether the FDA may be focused on a particular area of concern, such as a serious adverse event report or a whistleblower complaint.
The opening meeting is also the time to review expectations for facility tours and discussion topics, and it’s typically when a company receives its first list of specific records and documents to begin preparing.
Keep Senior Leadership in the Room, Briefly
Meanwhile, consultant McMinn said senior site leadership, including whoever holds the most responsibility at the site, should attend the opening meeting so the investigator knows who that person is. After that, he generally recommends that top leaders step back until the closing meeting, aside from potentially attending daily closing recaps.
“I would discourage those leaders from being there, because if anything around management responsibility or other things like that come up, you’d want to get your leaders prepared to speak to it, rather than just having them in the room and going into a lot of answers that can go places you don’t necessarily want an investigator to go,” McMinn said.
He described the approach as a way to keep the investigator’s questions directed toward quality professionals rather than an executive who may not be the right person to answer in the moment.
“At the end of the day, you want the investigator’s questions landing with the people who live in the quality system every day,” McMinn said. “That’s how you keep the conversation focused on the process, not on individual personalities.”
